Beyond Air®

AIT Therapeutics, commencing June 26, 2019 is named Beyond Air®. The Magic of Breathing®.

[Beyond Air® @BeyondAirInc]

LungFit PH has been awarded an Innovative Technology contract from @VizientInc , providing their members with first-in-class nitric oxide technology that delivers significant financial and operational benefits for a flat monthly fee. Learn more: https://t.co/kVpQYhOraY

[Beyond Air® @BeyondAirInc]

Beyond Air (#XAIR) welcomes Robert Goodman as our new #CEO, effective today. Bob brings decades of medtech and pharma leadership and is focused on one thing: accelerating adoption of LungFit® PH and scaling Beyond Air's impact for patients worldwide.
https://t.co/6RTrxOrKZt

[Beyond Air® @BeyondAirInc]

Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in one-on-one meetings at the The 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13 - 14 in Snowbird, Utah. Learn more: https://t.co/1WPLgitAN5

[Beyond Air® @BeyondAirInc]

Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in a fireside discussion and one-on-one meetings at the Piper Sandler Healthcare Conference on November 30, 2023, in New York City. Learn more: https://t.co/oOI9yxWp2K

[Beyond Air® @BeyondAirInc]

The Beyond Air Team wrapped up at @aarc_tweets  Conference in Nashville. Great attendance and interest in The LungFit PH and unlimited, on-demand iNO from room air - no cylinders, no cassettes, and hassle! Learn more: https://t.co/ieOdEiyCpJ

[Beyond Air® @BeyondAirInc]

Beyond Cancer, an affiliate of Beyond Air, presents positive first-in-human initial clinical data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in solid tumors during the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting. https://t.co/jP2JcYOxH6

[Beyond Air® @BeyondAirInc]

We’re ready for @aarc_tweets Congress! Visit booth 601 to see how LungFit PH generates and delivers iNO within seconds—no cylinders, no cassettes, no hassle.

Want to reserve a demo time for your team? Visit https://t.co/TW67VCi5fR.

#AARCCongress23 #CountdownToCongress

[Beyond Air® @BeyondAirInc]

We’re looking forward to exhibiting at @aarc_tweets Congress! Stop by booth 601 for a LungFit PH demo, the only cylinder-free system that provides unlimited, on-demand iNO from room air within seconds.

Want to reserve a demo time for your team? https://t.co/TW67VCi5fR

[Beyond Air® @BeyondAirInc]

During @aarc_tweets Respiratory Care Week, we’re thrilled to honor the unwavering commitment of respiratory therapists. Thank you for your clinical wisdom, passion, and dedication to the profession. #RCWeek23 #RTAppreciationWeek

[Beyond Air® @BeyondAirInc]

Beyond Cancer, an affiliate of Beyond Air, will present 2 posters with data from its ultra-high concentration nitric oxide (UNO) therapy program at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023. https://t.co/1bdOKoWhYa

[Beyond Air® @BeyondAirInc]

Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc., to present initial Phase I clinical data for ultra-high concentration nitric oxide therapy at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting on Nov. 3rd in San Diego. Learn more: https://t.co/I8qmaboDYr

[Beyond Air® @BeyondAirInc]

Beyond Air announced that it has entered into an agreement with @GetzHC_ANZ to commercialize the LungFit PH device in certain countries across the Asia-Pacific region. Learn more: https://t.co/DoywaSQn1n. #NitricOxide #GetzHealthcare

[Beyond Air® @BeyondAirInc]

We’re looking forward to exhibiting at the @IDNsummit! Join us at booth 4 to learn about FDA-approved LungFit PH, the first and only system that provides unlimited, on-demand generation of iNO from room air. No cylinders, no cassettes, and no hassle. #idnsummit

[Beyond Air® @BeyondAirInc]

Beyond Air reports financial results for the first quarter of fiscal year 2024. View the release for more information: https://t.co/Tgy4vtgV4p

[Beyond Air® @BeyondAirInc]

Beyond Air reports financial results for the fourth quarter of fiscal year 2023. View the release for more information: https://t.co/E8rM3imKSm

[Beyond Air® @BeyondAirInc]

Watch the webcast to learn more about our licensing agreement and acquisition of commercial rights to develop an nNOS inhibitor that could reverse the effects of autism. The first-in-human study planned for 2025: https://t.co/QuK5WL1103

[Beyond Air® @BeyondAirInc]

Beyond Air announces agreement with @HebrewU to acquire commercial rights for a neuronal nitric oxide synthase (nNOS) inhibitor being developed to treat autism spectrum disorder. The first-in-human study is planned for 2025: https://t.co/TmP1ep29J9

[Beyond Air® @BeyondAirInc]

Neonatal Intensive Care interviewed Beyond Air's Director of Clinical Services, Jeff Griebel, to discuss the LungFit PH. Learn about its benefits compared to cylinder-based systems from a respiratory therapist and NO expert. Full article: https://t.co/bIh7UrGnwz

[Beyond Air® @BeyondAirInc]

Beyond Air’s CEO, Steve Lisi, was interviewed by @RTMagazine alongside @VERObiotech Dir of Clinical Ed to discuss the impact of cylinder-free systems on iNO delivery, innovations they’re driving in the market, as well as BA’s robust iNO pipeline:https://t.co/NJhkTuzp7R

[Beyond Air® @BeyondAirInc]

@BeyondAirInc, affiliate Beyond Cancer, presented in vivo and in vitro data at @AACR 2023 supporting the potential of novel ultra-high concentration nitric oxide therapy to treat solid tumors as a single agent and in combination with checkpoint inhibitors. https://t.co/mc8ap9rTll